Core Viewpoint - Jaguar Health (NASDAQ:JAGX) stock has significantly declined following the failure of a Phase 3 clinical trial for crofelemer, which did not meet its primary endpoint [2][3]. Group 1: Clinical Trial Results - The Phase 3 clinical trial evaluated crofelemer for the prophylaxis of diarrhea in adult cancer patients with solid tumors, covering 10 different tumor types [4]. - Crofelemer was only effective in patients with breast and respiratory cancers, indicating limited efficacy across the studied tumor types [2][4]. - The trial's failure has led to heavy trading activity, with over 12 million shares changing hands, far exceeding the average daily trading volume of approximately 800,000 shares [3]. Group 2: Stock Market Impact - As of Tuesday afternoon, JAGX stock has dropped by 55.2% due to the negative trial results [6]. - The significant decline in stock price has prompted traders to sell shares aggressively, reflecting investor sentiment following the trial's outcome [3][6].

Core Viewpoint - Jaguar Health is implementing a one-for-60 reverse stock split to increase its share price and comply with Nasdaq's minimum bid price rule, aiming to attract institutional investors [3]. Group 1: Reverse Stock Split Details - The reverse stock split will consolidate 60 shares of JAGX into one share, with trading on a split-adjusted basis starting Thursday [1]. - Post-split, shares will continue to trade under the JAGX ticker on the Nasdaq Capital Market, with a new CUSIP number of 47010C805 [2]. Group 2: Market Reaction - As of Monday morning, JAGX stock has decreased by 40.3% [4].

Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Lisa Conte - Founder, President and CEO Carol Lizak - CFO Conference Call Participants Operator Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements, relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

Jaguar Health (NASDAQ:JAGX) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new license for a chemo mouth treatment.Jaguar Health is looking to treat chemo mouth, a side effect of chemotherapy, with Gelclair. This treatment already has approval from the Food and Drug Administration (FDA).Jaguar Health is licensing Gelclair from U.K.-based Venture Life Group. The product is a gel that makes it easier for patients undergoing chemotherapy to eat, drink, swallow, speak and slee ...

Former meme stock Jaguar Health (NASDAQ:JAGX) has won the approval of certain measures meant to help maintain its Nasdaq listing. These include an extension to Aug. 13 to regain compliance by getting its price over $1 as well as JAGX stockholder approval of a potential reverse stock split.Jaguar Health is delaying the reverse split as it seeks approval on a preventative treatment of cancer therapy-related diarrhea. The study is called OnTarget.This news is sending JAGX stock up 20% as of this writing. The s ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2023 Earnings Call Transcript April 1, 2024 8:30 AM ET Company Participants Lisa Conte - Founder, President and CEO Carol Lizak - CFO Operator Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends, and productive initiat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 46-2956775 (State or other jurisd ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Lisa Conte - President & CEO Carol Lizak - CFO Operator Good morning. Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as Contenued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends, and product ini ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdict ...